PATENT CLAIM ANALYSIS

Application Number: 16178865
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "487000"]

Abstract:
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA B  receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA B  receptor agonist.

Claim (Index 1):
An oral extended release dosage form that provides at least the same therapeutic efficacy and reduced adverse events as compared to an immediate release reference dosage form containing the same daily dose of arbaclofen (ARBAC), wherein:\n a) said extended release dosage form provides a higher AUC 0-inf  and higher Cmax and a longer Tmax than that provided by said immediate release reference dosage form; or b) said extended release dosage form provides an AUC 0-inf  and a Cmax that is at least the same as the AUC 0-inf  and Cmax, respectively, provided by said immediate release reference dosage form and a longer Tmax than that provided by said immediate release reference dosage form.

Metadata:
- Claim Count in Document: 101.0
- Percentile: 98.0
- Lexical Diversity: 1.47222
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15673781', '15680434', '15048743', '15919422', '15919436']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8404129582107152
- 35 USC 102 Novelty (BERT): 0.6241556343808277
- Combined Prediction Score: 0.8187872258277265
- Mean Citation Score: 562.2168720000002
- Max Citation Score: 573.3431
- Similarity Product: 521.3267837906479

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test